The blood product industry should prevent excess after entering the period of rapid rise.

The business community reported on February 28 that the tightness and shortage of clinical blood products continued to ease over the past few years. On February 22, Liu Wenfang, a professor of blood transfusion at the Chinese Academy of Medical Sciences and a senior expert in the field of blood products, on this year and future blood products. The market supply situation gives a reassuring answer - With the simultaneous increase in imports and domestic quantities, the market shortage of blood products, especially the most used clinical albumin, has been reversed, and our blood product industry is already Rapid rise.

Insufficiency

Plasma protein products are mainly prepared from healthy human plasma and prepared using separation, purification techniques or bioengineering techniques. They are biologically active special drugs for the prevention and treatment of medical emergencies, life-saving and certain specific genetic diseases. There is an irreplaceable role for other drugs.

According to Liu Wenfang, the current global market for human-derived plasma protein products exceeds US$6.9 billion in sales. The driving force of this market is mainly from the United States and Europe, especially the intravenous injection of human immunoglobulin. The driving force of the Chinese market is mainly from albumin and plasma-derived factor VIII concentrates. Around 2004, in the blood product market in China, the proportion of albumin once reached 80%. This is because China is one of the earliest countries to develop and produce albumin. At the same time, China is still a big country with hepatitis. Patients with severe hepatitis need to add a lot of albumin. The shortage of blood products in China is mainly due to insufficient supply of albumin.

According to public data released by China's blood product batches, in 2010, the market capacity of albumin in our country was approximately 13 million bottles, of which approximately 6.5 million bottles were imported, and domestic and imported products accounted for half of each.

An insider of Huadong Medicine, who declined to be named, said that in recent years, the annual growth rate of the albumin market supply has been around 30%. In 2010, the market supply has reached the national supply around 2004, but with the new rural cooperative With the advancement of the basic medical insurance system, the market demand for human albumin is also increasing. In 2004, the State carried out rectification of apheresis plasma station, restructured the property rights of plasmapheresis station in 2006, and implemented market-oriented measures such as one-on-one management of blood product companies by plasma stations, which drastically reduced the amount of domestic plasma raw materials. Some small-scale blood product manufacturers have withdrawn from the market. However, at the same time, due to the limitation of the technical level, domestic normative enterprises have not kept pace with the supply. It is understood that the utilization of plasma in domestic companies is not high. In general, 1 ton of plasma can separate 2700 bottles of albumin (10 grams per bottle), 1400 bottles of gamma globulin, 800 bottles of coagulation factors, and at least 6 products. However, most companies in China can only separate 2 to 3 products. There are few advantageous companies that can separate more than 6 varieties.

In order to ease the tight supply of blood products, the government has implemented a zero-tariff system for human blood albumin, immunoglobulin and other blood products since 2009, and has issued batches of human immunoglobulin products since June 2007. Since January 1, 2008, all batches of blood products that have been marketed have been issued in batches.